Research Progress of Predictive Markers for Efficacy of Immune Checkpoint Inhibitors for Esophageal Squamous Cell Carcinoma

VernacularTitle:食管鳞癌免疫检查点抑制剂疗效预测标志物的研究进展
Author: Rongshan CHEN ¹ ; Liyan XUE
Author Information

1. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Publication Type:Research Article
Keywords: Immune checkpoint; Tumor microenvironment; Immunotherapy; Biomarkers; Esophageal squamous cell carcinoma
From: Cancer Research on Prevention and Treatment 2022;49(12):1302-1306
CountryChina
Language:Chinese
Abstract: Esophageal squamous cell carcinoma (ESCC) is the main prevalent histological type of esophageal cancer worldwide, with a high mortality and poor prognosis due to advanced stage at diagnosis. Surgical resection after neoadjuvant therapy is the main treatment for ESCC. With the rise of immunotherapy, immunotherapy on ESCC has been shown to improve outcomes, especially the immune checkpoint inhibitors (ICIs). As the efficacy of immunotherapy for ESCC is limited, it is helpful to screen patients who may benefit from immunotherapy by looking for predictive biomarkers of efficacy of immunotherapy. In this paper, based on the current literature on immunotherapy and related biomarkers, we review the research progress on predictive markers of ICIs for ESCC, in hopes of providing assistances for the precise treatment and prognosis determination.